Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Cannabinoid-focused pharmaceutical company MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced Monday its financial results for the three months ended June 30, 2023, revealing revenue of CA$9.58 million ($7.11 million) compared to CA$4.36 million in the same period last year.
“In Q2, we continued to make progress by growing our revenue base, improving gross margins, reducing expenses and reducing cash burn as we drive towards profitability.” Greg Hunter, CFO, MediPharm Labs stated. “We have also demonstrated that we can quickly integrate and drive synergies through acquisitions."
Recent Milestones
David Pidduck, CEO, MediPharm Labs commented, "We are very happy with our Q2 performance lead by the smooth VIVO integration that is ahead of all cost synergy targets. We are excited to have new employees, new business units, new products and capabilities and new investors and stakeholders."
MediPharm shares were trading 7.97% lower at $0.0589 per share at the time of publishing Monday morning.
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Photo: Courtesy of Terrance Barksdale via Pexels